Kazia Therapeutics preclinical data links paxalisib to improved immunotherapy response
Kazia Therapeutics reported preclinical data showing paxalisib reprograms immunotherapy-resistant MSS/pMMR colorectal cancer and enhances response to immunotherapy.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.